IntelGenx Corp. Announces License Agreement for the Commercialization of CPI-300 in the United States  
2/14/2012 9:44:29 AM

SAINT LAURENT, Quebec, Feb. 14, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX.V - News) (OTCBB:IGXT.OB - News) ("IntelGenx") today announced that it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC ("Edgemont") for the commercialization of IntelGenx' lead product CPI-300 in the United States (U.S.).